Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

KEYTRUDA: resectable locally advanced Squamous Cell Cancer with PD-L1 stated without a specific alteration (neoadjuvant)

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.

Broader topic: Squamous Cell Carcinoma

Source population
Not part of this definition
Disease extent
locally-advanced
Treatment line
neoadjuvant
Stage
Not part of this definition
Resectability
resectable
Biomarkers, prior therapy and derivation
molecular
  1. gene
    PD-L1
    alteration
    stated without a specific alteration
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for KEYTRUDA (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice